drugset / Trial / NCT02232087

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

NCT02232087

Phase 1 Completed 52 enrolled Kindeva Drug Delivery
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to test the body's response to several doses of two different inhalation products in healthy volunteers.

Timeline

Start
2014-07
Primary completion
2014-10
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 250 ug Other
Subject Fluticasone propionate Other / unclassified 750 ug Other
Subject Fluticasone propionate Other / unclassified 1500 ug Other
Subject Salmeterol Other / unclassified 50 ug Other
Subject Salmeterol Other / unclassified 150 ug Other
Subject Salmeterol Other / unclassified 300 ug Other

Indications

No indication recorded.